Cargando…

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer

Cyclin-dependent kinase 2 (CDK2) regulates the progression of the cell cycle and is critically associated with tumor growth. Selective CDK2 inhibition provides a potential therapeutic benefit against certain tumors. Purines and related heterocycle (e.g., R-Roscovitine) are important scaffolds in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hanzhi, Zhu, Yue, Zhao, Zhiyuan, Du, Jintong, Yang, Xinying, Fang, Hao, Hou, Xuben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110766/ https://www.ncbi.nlm.nih.gov/pubmed/35592410 http://dx.doi.org/10.3389/fphar.2022.864342

Ejemplares similares

PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer
por: Hou, Xuben, et al.
Publicado: (2021)

Tricyclic Nucleobase Analogs and Their Ribosides as Substrates and Inhibitors of Purine-Nucleoside Phosphorylases III. Aminopurine Derivatives
por: Stachelska-Wierzchowska, Alicja, et al.
Publicado: (2020)

G-quadruplex structure and stability illuminated by 2-aminopurine phasor plots
por: Buscaglia, Robert, et al.
Publicado: (2012)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

6‐Substituted 2‐Aminopurine‐2′‐deoxyribonucleoside 5′‐Triphosphates that Trace Cytosine Methylation
por: von Watzdorf, Janina, et al.
Publicado: (2016)

Nucleotide flipping by restriction enzymes analyzed by 2-aminopurine steady-state fluorescence
por: Tamulaitis, Gintautas, et al.
Publicado: (2007)

High-Throughput Exonuclease Assay Based on the Fluorescent Base Analogue 2-Aminopurine
por: Botto, Margherita M., et al.
Publicado: (2023)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Probing dynamics of HIV-1 nucleocapsid protein/target hexanucleotide complexes by 2-aminopurine
por: Avilov, S. V., et al.
Publicado: (2008)

Inhibition of Endoplasmic Reticulum Stress and Atherosclerosis by 2-Aminopurine in Apolipoprotein E-Deficient Mice
por: Zhou, Lichun, et al.
Publicado: (2013)

A highly specific sodium aptamer probed by 2-aminopurine for robust Na(+) sensing
por: Zhou, Wenhu, et al.
Publicado: (2016)

Influence of the Solvent on the Stability of Aminopurine Tautomers and Properties of the Amino Group
por: Jezuita, Anna, et al.
Publicado: (2023)

Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Boudou, Cédric, et al.
Publicado: (2022)

SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer
por: Liu, Peng, et al.
Publicado: (2018)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Frontiers Production Office,
Publicado: (2023)

8-vinyl-deoxyadenosine, an alternative fluorescent nucleoside analog to 2′-deoxyribosyl-2-aminopurine with improved properties
por: Gaied, Nouha Ben, et al.
Publicado: (2005)

Designing and Synthesis of New Isatin Derivatives as Potential CDK2 Inhibitors
por: Czeleń, Przemysław, et al.
Publicado: (2022)

Determination of the secondary structure of group II bulge loops using the fluorescent probe 2-aminopurine
por: Dishler, Abigael L., et al.
Publicado: (2015)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
por: Sun, Chao-Yue, et al.
Publicado: (2022)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer
por: Sang, Xiaoye, et al.
Publicado: (2022)

Current landscape of personalized clinical treatments for triple-negative breast cancer
por: Zhang, Jun, et al.
Publicado: (2022)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors
por: Zhang, Gaomin, et al.
Publicado: (2018)

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
por: Umfress, Alan, et al.
Publicado: (2022)

2-Aminopurine Enhances the Oncolytic Activity of an E1b-Deleted Adenovirus in Hepatocellular Carcinoma Cells
por: Sharon, David, et al.
Publicado: (2013)

Inhibition of porcine reproductive and respiratory syndrome virus by interferon-gamma and recovery of virus replication with 2-aminopurine
por: Rowland, R. R. R., et al.
Publicado: (2001)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Ghallab, Alaa M., et al.
Publicado: (2022)

Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway
por: Yang, Ting, et al.
Publicado: (2021)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

Time-resolved fluorescence of 2-aminopurine as a probe of base flipping in M.HhaI–DNA complexes
por: Neely, Robert K., et al.
Publicado: (2005)

Inhibition of ER Stress by 2-Aminopurine Treatment Modulates Cardiomyopathy in a Murine Chronic Chagas Disease Model
por: Ayyappan, Janeesh Plakkal, et al.
Publicado: (2019)

Editorial: Targeting triple negative breast cancer by natural compounds
por: Kumar, Shashank, et al.
Publicado: (2023)

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2019)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
por: Mao, Long-fei, et al.
Publicado: (2020)

Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress Triple-Negative Breast Cancer Tumorigenesis and Development
por: Peng, Fu, et al.
Publicado: (2020)

Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
por: Zhu, Haibo, et al.
Publicado: (2021)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3djgph9e1692hphhaovqvqejk9